[3H]spiperone binding in the nigrostriatal system in human brain. 1984

M Ruberg, and B Bokobza, and F Javoy-Agid, and J C Montfort, and Y Agid

The characteristics of [3H]spiperone binding in human brain were compared in three areas of the nigrostriatal pathway: areas containing the nerve terminals (caudate nucleus, putamen and pallidum); the area containing the cell bodies (substantia nigra pars compacta); the area containing the dendrites (pars reticulata). The affinity constants were calculated from saturation binding curves and from the kinetics of association and dissociation. The pharmacological profiles of the receptors was also established by displacement studies. The affinity constants and pharmacological profiles were similar in the striatum and the substantia nigra, although the latter contained a much smaller number of sites. In the substantia nigra, however, curved Scatchard plots were obtained, indicating that a second lower affinity site binding [3H]spiperone was also present. A considerable proportion (50%) of [3H]spiperone binding to nigral membranes could be displaced by the serotonin antagonist cinanserine , compared to the striatum (20%). The effect of post-mortem conditions on binding levels was studied in the rat. A loss of 20% occurred during the first hours after death, but was stable by 6 h until at least 24 h.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008297 Male Males
D009411 Nerve Endings Branch-like terminations of NERVE FIBERS, sensory or motor NEURONS. Endings of sensory neurons are the beginnings of afferent pathway to the CENTRAL NERVOUS SYSTEM. Endings of motor neurons are the terminals of axons at the muscle cells. Nerve endings which release neurotransmitters are called PRESYNAPTIC TERMINALS. Ending, Nerve,Endings, Nerve,Nerve Ending
D010646 Phentolamine A nonselective alpha-adrenergic antagonist. It is used in the treatment of hypertension and hypertensive emergencies, pheochromocytoma, vasospasm of RAYNAUD DISEASE and frostbite, clonidine withdrawal syndrome, impotence, and peripheral vascular disease. Fentolamin,Phentolamine Mesilate,Phentolamine Mesylate,Phentolamine Methanesulfonate,Phentolamine Mono-hydrochloride,Regitine,Regityn,Rogitine,Z-Max,Mesilate, Phentolamine,Mesylate, Phentolamine,Methanesulfonate, Phentolamine,Mono-hydrochloride, Phentolamine,Phentolamine Mono hydrochloride
D011180 Postmortem Changes Physiological changes that occur in bodies after death. Adipocere,Algor Mortis,Cruor,Livor Mortis,Change, Postmortem,Changes, Postmortem,Postmortem Change
D011699 Putamen The largest and most lateral of the BASAL GANGLIA lying between the lateral medullary lamina of the GLOBUS PALLIDUS and the EXTERNAL CAPSULE. It is part of the neostriatum and forms part of the LENTIFORM NUCLEUS along with the GLOBUS PALLIDUS. Nucleus Putamen,Nucleus Putamens,Putamen, Nucleus,Putamens,Putamens, Nucleus
D002069 Butaclamol A benzocycloheptapyridoisoquinolinol that has been used as an antipsychotic, especially in schizophrenia. AY-23,028,Butaclamol Hydrochloride,AY 23,028,AY23,028,Hydrochloride, Butaclamol
D002090 Butyrophenones Compounds containing phenyl-1-butanone.
D002421 Caudate Nucleus Elongated gray mass of the neostriatum located adjacent to the lateral ventricle of the brain. Caudatus,Nucleus Caudatus,Caudatus, Nucleus,Nucleus, Caudate
D002928 Cinanserin A serotonin antagonist with limited antihistaminic, anticholinergic, and immunosuppressive activity. Cinanserin Hydrochloride,Cinanserin Monohydrochloride,SQ-10,643,SQ-16,167,Hydrochloride, Cinanserin,Monohydrochloride, Cinanserin,SQ 10,643,SQ 16,167,SQ10,643,SQ16,167

Related Publications

M Ruberg, and B Bokobza, and F Javoy-Agid, and J C Montfort, and Y Agid
August 1978, Life sciences,
M Ruberg, and B Bokobza, and F Javoy-Agid, and J C Montfort, and Y Agid
October 1985, European journal of pharmacology,
M Ruberg, and B Bokobza, and F Javoy-Agid, and J C Montfort, and Y Agid
August 1978, Life sciences,
M Ruberg, and B Bokobza, and F Javoy-Agid, and J C Montfort, and Y Agid
March 1985, Biulleten' eksperimental'noi biologii i meditsiny,
M Ruberg, and B Bokobza, and F Javoy-Agid, and J C Montfort, and Y Agid
June 1981, Brain research,
M Ruberg, and B Bokobza, and F Javoy-Agid, and J C Montfort, and Y Agid
April 1998, The Journal of comparative neurology,
M Ruberg, and B Bokobza, and F Javoy-Agid, and J C Montfort, and Y Agid
September 1985, Life sciences,
M Ruberg, and B Bokobza, and F Javoy-Agid, and J C Montfort, and Y Agid
January 1991, Journal of receptor research,
M Ruberg, and B Bokobza, and F Javoy-Agid, and J C Montfort, and Y Agid
July 1982, European journal of pharmacology,
M Ruberg, and B Bokobza, and F Javoy-Agid, and J C Montfort, and Y Agid
January 1990, Journal of psychiatric research,
Copied contents to your clipboard!